{"id":"W3025475588","doi":"10.1136/lba2019.16","title":"P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma","year":2020,"lang":"en","type":"article","venue":"Poster presentations","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; McMaster University; Juravinski Cancer Centre","funders":"Pfizer","keywords":"Trametinib; Pembrolizumab; Dabrafenib; Medicine; Tolerability; Melanoma; Internal medicine; Oncology; Adverse effect; Vemurafenib; Cancer research; Immunotherapy; MAPK/ERK pathway; Biology; Cancer; Metastatic melanoma; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003280625,0.0001641316,0.0001739281,0.00002781462,0.0001253885,0.00005092757,0.0001230716,0.00007313117,0.00004024192],"category_scores_gemma":[0.0001194423,0.000129743,0.0000472309,0.00008185431,0.0000617312,0.00001285246,0.0000823825,0.00005754366,0.000008097019],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00000519855,"about_ca_system_score_gemma":0.0001034386,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001233639,"about_ca_topic_score_gemma":0.00004123532,"domain_scores_codex":[0.9990282,0.00004519799,0.0002019328,0.0003677778,0.0001206683,0.0002362361],"domain_scores_gemma":[0.9993817,0.00004064163,0.00008267045,0.000196665,0.0001233308,0.000175007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04882392,0.002116761,0.606193,0.001520544,0.002079833,0.000155062,0.01945806,0.0009953418,0.184306,0.001239198,0.1125063,0.02060597],"study_design_scores_gemma":[0.05520711,0.03966098,0.4087159,0.0001512744,0.0009881875,0.000222587,0.002386608,0.002884048,0.2796984,0.0004431294,0.2061391,0.003502697],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960538,0.00006975441,0.001410945,0.000641753,0.00009727129,0.0007787833,0.0002020946,0.00002243027,0.000723166],"genre_scores_gemma":[0.9966412,0.0000122815,0.0008825949,0.0007698284,0.0001743788,0.00009915612,0.0008634054,0.00003287283,0.0005243223],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1974771,"threshold_uncertainty_score":0.5290765,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02389815023060663,"score_gpt":0.2698003080044721,"score_spread":0.2459021577738655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}